Late presentation of sorafenib-associated rash: a case report
<p>Abstract</p> <p>Introduction</p> <p>Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for the treatment of hepatocellular carcinoma. Rash is one of the most common side effects of its use, generally appearing within days to a few weeks of commen...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-10-01
|
| Series: | Journal of Medical Case Reports |
| Online Access: | http://www.jmedicalcasereports.com/content/4/1/338 |